openPR Logo
Press release

Deadline on June 4th coming up in Lawsuit for Investors in shares of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT)

A Deadline is coming up on June 4, 2024 in the lawsuit for certain investors in Checkpoint Therapeutics, Inc. (NASDAQ: CKPT).

A Deadline is coming up on June 4, 2024 in the lawsuit for certain investors in Checkpoint Therapeutics, Inc. (NASDAQ: CKPT).

A deadline is coming up on June 4, 2024 in the lawsuit filed for certain investors of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) over alleged securities laws violations by Checkpoint Therapeutics, Inc.

Investors who purchased shares of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) have certain options and there are strict and short deadlines running. Deadline: June 4, 2024. NASDAQ: CKPT stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges on behalf of purchasers of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) common shares between March 10, 2021 and December 15, 2023, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between March 10, 2021 and December 15, 2023, the defendants made false and/or misleading statements and/or failed to disclose that Checkpoint had overstated its oversight of, and/or its establishment of adequate manufacturing standards and controls over, its third-party contract manufacturers, that accordingly, there were one or more issues with the Company's third-party contract manufacturing organization ("CMO") for cosibelimab, that all the foregoing reduced the likelihood that the FDA would approve the cosibelimab BLA in its present form, that as a result, the manufacturing, regulatory, and commercial prospects of cosibelimab were overstated, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Deadline on June 4th coming up in Lawsuit for Investors in shares of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) here

News-ID: 3509104 • Views:

More Releases from Shareholders Foundation, Inc.

Investigation announced for Long-Term Investors in shares of PepGen Inc. (NASDAQ: PEPG) over potential Wrongdoing
Investigation announced for Long-Term Investors in shares of PepGen Inc. (NASDAQ …
An investigation was announced for current long-term investors in shares of PepGen Inc. (NASDAQ: PEPG) concerning potential breaches of fiduciary duties by certain directors of PepGen Inc. Investors who are current long term investors in PepGen Inc. (NASDAQ: PEPG) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: PEPG
Novo Nordisk A/S (NYSE: NVO) Investor Alert: Lawsuit alleges False and Misleading Statements
Novo Nordisk A/S (NYSE: NVO) Investor Alert: Lawsuit alleges False and Misleadin …
An investor, who purchased shares of Novo Nordisk A/S (NYSE: NVO), filed a lawsuit in the U.S. District Court for the District of New Jersey over alleged violations of Federal Securities Laws by Novo Nordisk A/S in connection with certain allegedly false and misleading statements. Investors who purchased shares of Novo Nordisk A/S (NYSE: NVO) have certain options and for certain investors are short and strict deadlines running. Deadline: September 30,
Lawsuit filed for Investors who lost money with shares of PubMatic, Inc. (NASDAQ: PUBM)
Lawsuit filed for Investors who lost money with shares of PubMatic, Inc. (NASDAQ …
An investor, who purchased shares of PubMatic, Inc. (NASDAQ: PUBM), filed a lawsuit over alleged violations of Federal Securities Laws by PubMatic, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of PubMatic, Inc. (NASDAQ: PUBM) have certain options and for certain investors are short and strict deadlines running. Deadline: October 20, 2025. NASDAQ: PUBM investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)
Reckitt Benckiser Group plc (OTC: RBGLY) Long Term Investor Alert: Investigation of potential Wrongdoing
Reckitt Benckiser Group plc (OTC: RBGLY) Long Term Investor Alert: Investigation …
An investigation on behalf of current long-term investors in shares of Reckitt Benckiser Group plc (OTC: RBGLY) concerning potential breaches of fiduciary duties was announced. Investors who are current long term investors in Reckitt Benckiser Group plc (OTC: RBGLY) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in OTC: RBGLY

All 5 Releases


More Releases for Checkpoint

Comparative Effectiveness of TIGIT Antibodies and Other Checkpoint Inhibitors
The comparative effectiveness of TIGIT antibodies and other checkpoint inhibitors is a topic of significant interest in the field of cancer immunotherapy. Immune checkpoint inhibitors have revolutionized cancer treatment by unleashing the immune system's ability to attack tumors. While PD-1 and CTLA-4 inhibitors have shown remarkable success, TIGIT antibodies offer a new approach with potentially complementary mechanisms. Download Report https://www.kuickresearch.com/report-anti-tigit-antibody-anti-tigit-antibodies-fda-approved-tigit-antibody-tigit-inhibitors-tigit-drugs-approved-tigit-expression-tigit-ligand-tigit-gene PD-1 inhibitors, such as pembrolizumab and nivolumab, block the PD-1 receptor on T
Checkpoint Inhibitors Market Report 2024: Advancing Cancer Treatments
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033. Checkpoint Inhibitors Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance. The Market Size Is Expected To Reach $55.64 billion In 2028 At
Checkpoint Inhibitors Competitive Landscape Report 2023
DelveInsight's, "Checkpoint Inhibitors Competitive Landscape 2023" report provides comprehensive insights about 180+ Checkpoint Inhibitors Companies and 250+ drugs in the Checkpoint inhibitors Competitive landscape. It covers the Checkpoint Inhibitors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Checkpoint Inhibitors Competitive Landscape Report • DelveInsight's Checkpoint Inhibitors report depicts a robust space with 180+ Glioma
Checkpoint Inhibitor Refractory Cancer Market
Checkpoint Inhibitor Refractory Cancer Market Overview The global Checkpoint Inhibitor Refractory Cancer Market is poised for significant growth, anticipating a high CAGR during the forecast period from 2023 to 2030. Understanding Checkpoint Inhibitor Refractory Cancer Refractory cancer, which might not respond to treatments immediately or might develop resistance later, has driven significant growth and transformation in the global checkpoint inhibitor refractory cancer market. The interest of oncologists in the potential antitumor activity of
Immune Checkpoint Inhibitors Market: Current Evidence And Future Perspectives Of …
Stratagem Market Insights delivers key insights for the Immune Checkpoint Inhibitors market in its published report, which include global industry analysis, Size, Growth, Opportunities, Emerging Trends, Challenges, and Geographic Regions over the forecast period (2021-2028). In terms of revenue, the global Immune Checkpoint Inhibitors market is projected to grow at a CAGR of XX% during the forecast period, owing to several factors about which SMI offers detailed insights and forecasts
Immune Checkpoint Inhibitor
Immune Checkpoint Inhibitors Market Insights 2019, Global and Chinese Scenario is a professional and indepth study on the current state of the global Immune Checkpoint Inhibitors industry with a focus on the Chinese market. The report provides key statistics on the market status of the Immune Checkpoint Inhibitors manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Overall, the report provides an